The ACTC1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human A2780 ovarian carcinoma cell line, designed to disrupt the ACTC1 gene. This loss-of-function model enables systematic investigation of cardiac alpha-actin in a non-muscle epithelial cancer context, circumventing the limitations of traditional RNA interference or pharmacological inhibition. As a polyclonal pool, the product provides a heterogeneous population of cells with targeted gene disruption, allowing functional studies without clonal selection artifacts. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, ensuring stable ablation of ACTC1 expression across the cell population, as confirmed by western blotting and immunofluorescence assays.
The A2780 cell line is a well-characterized model of human ovarian carcinoma, first established from an untreated patient tumor and widely employed in cancer biology research. These epithelial tumor cells retain key features of ovarian cancer, including rapid proliferation, tumorigenicity in xenograft models, and the capacity for migration and invasion??processes intimately linked to actin cytoskeleton dynamics. A2780 cells have been instrumental in studying drug resistance mechanisms, metastasis, and intracellular signaling, making them a robust platform for interrogating the role of actin isoforms in malignant phenotypes. Their human origin and ovarian lineage provide a clinically relevant background for translational studies.
ACTC1 encodes cardiac alpha-actin, the predominant actin isoform of striated muscle thin filaments, playing a critical role in sarcomere organization and contractile force generation. Beyond its canonical function in muscle contraction, cardiac alpha-actin contributes to cytoskeletal architecture in non-muscle cells, where it influences cell morphology, adhesion, and motility. ACTC1 is transcriptionally regulated by a network of upstream factors including MEF2, SRF, myocardin, and TGF-beta, and is responsive to mechanical stress. The protein engages in direct interactions with myosin, tropomyosin, troponin, alpha-actinin, cofilin, and profilin, forming dynamic complexes that govern actin filament turnover and organization. Downstream, ACTC1 is essential for sarcomere assembly, muscle contraction, cell motility, and cytoskeletal reorganization, placing it at the nexus of mechanotransduction and cellular dynamics.
In the A2780 ovarian carcinoma context, ACTC1 knockout likely perturbs actin cytoskeleton dynamics, leading to altered cell morphology, adhesion strength, and migratory capacity??phenotypes of high relevance to cancer metastasis. Although ACTC1 is primarily associated with cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, its unanticipated expression or functional roles in epithelial cancers are increasingly recognized. This model thus bridges cardiac actin biology and oncology, enabling researchers to dissect how a sarcomeric actin contributes to non-muscle cell behavior. The polyclonal knockout population avoids potential adaptive changes seen in single-cell clones, preserving the variability inherent to tumor cell lines and offering a more physiologically representative system for functional genomics and drug sensitivity testing.
This knockout product is ideally suited for detailed functional assays aimed at deciphering actin-dependent processes in ovarian cancer. Researchers can employ wound healing and transwell invasion assays to quantify migration and invasion defects, adhesion assays to measure cell-substrate attachment, and immunofluorescence microscopy to visualize cytoskeletal reorganization. Transcriptomic changes can be profiled by RNA-seq, while cell proliferation and drug sensitivity testing allow evaluation of responses to actin-targeting compounds. The model further facilitates the study of actin-related cardiomyopathies in a cancer cell context, exploring potential cross-talk between oncogenic signaling and sarcomeric protein function. For technical inquiries and ordering information, please contact Ascent Research.
